Table 1.
Characteristics of the multiple myeloma (MM) patients.
| Variable | Number of Patients (%) |
|---|---|
| Gender (76/76 patients) | |
| Male | 44 (57.9%) |
| Female | 32 (42.1%) |
| M-protein isotype (75/76 patients) | |
| IgG | 44 (58.7%) |
| IgA | 17 (22.7%) |
| IgD | 2 (2.7%) |
| Kappa light chain | 7 (9.2%) |
| Lambda light chain | 3 (4.0%) |
| Not typed | 2 (2.7%) |
| del(17p) (71/76 patients) | |
| Absence | 59 (83.1%) |
| Presence | 12 (16.9%) |
| t(4;14) (70/76 patients) | |
| Absence | 62 (88.6%) |
| Presence | 8 (11.4%) |
| t(14;16) (68/76 patients) | |
| Absence | 67 (98.5%) |
| Presence | 1 (1.5%) |
| (+1q) (54/76 patients) | |
| Absence | 30 (55.6%) |
| Presence | 24 (44.4%) |
| ISS 1 stage (74/76 patients) | |
| I | 15 (20.3%) |
| II | 25 (33.8%) |
| III | 34 (45.9%) |
| R-ISS 2 stage (69/76 patients) | |
| I | 11 (15.9%) |
| II | 40 (58.0%) |
| III | 18 (26.1%) |
| Bone disease (72/76 patients) | |
| No | 22 (30.6%) |
| Yes | 50 (69.4%) |
| WBLDCT 3 osteolysis (56/76 patients) | |
| No | 18 (32.1%) |
| Yes | 38 (67.9%) |
1 International Staging System; 2 Revised International Staging System; 3 Whole-body low-dose computed tomography.